Siemens Healthineers Ag · XETR:SHL

Siemens Healthineers — Q4 FY2021 Earnings Presentation

14 slides from Siemens Healthineers's earnings presentation, Nov 4, 2021

  1. Slide 1: Q4 Analyst Call

    Q4 Analyst Call Bernd Montag, CEO | Jochen Schmitz, CFO November 4, 2021

  2. Slide 2: Safe harbour statement

    Safe harbour statement This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be

  3. Slide 3: FY2021 – outstanding performance in a demanding environment

    FY2021 – outstanding performance in a demanding environment Key achievements in FY2021 A record year Comparable revenue growth1 • Outstanding performance: gained market share, seized new opportunities, launched breakthrough innovations, embraced Outlook +19.3% 17-19% sustainability • Strong financia

  4. Slide 4: Outlook FY2022

    Outlook FY2022 Comparable revenue growth1, 2 Adj. basic earnings per share2 Ex antigen: 5 to 7% Ex antigen: +17 to +23% 0 to 2% €2.08 to €2.20 Q4 FY2021 1 Year-over-year on a comparable basis, excluding currency translation and portfolio effects as well as effects in line with revaluation of contrac

  5. Slide 5: Q4 – a strong finish in a record year

    Q4 – a strong finish in a record year Revenue (€m) • 14% revenue growth1 and 1.172 equipment book-to-bill Comparable +14.4% Growth1 • Excellent 22% revenue growth1 at Diagnostics; 5,164 therein ~€160m antigen test revenue 3,876 • Continued strong growth1 in Imaging (12%) and Advanced Therapies (14%)

  6. Slide 6: Excellent growth in all businesses, FX headwinds in margins for Imaging and Advanced Therapies

    Excellent growth in all businesses, FX headwinds in margins for Imaging and Advanced Therapies Imaging (€m) Diagnostics (€m) Advanced Therapies (€m) Comparable +11.6% +22.3% +14.5% Growth1 Adjusted 2,447 2,757 1,038 1,278 432 499 revenue Q4 FY2020 Q4 FY2021 Q4 FY2020 Q4 FY2021 Q4 FY2020 Q4 FY2021 Ma

  7. Slide 7: Recovery of the Varian business in full swing – equipment book-to-bill at 1.59

    Recovery of the Varian business in full swing – equipment book-to-bill at 1.59 Order intake Revenue (€m) Profitability (€m) Equipment book-to-bill Adjusted Revenue1 Adj. EBIT (margin) 1.6 1.4 591 709 98 122 (16.6%) (17.3%) Q3 FY2021 Q4 FY21021 Q3 FY2021 Q4 FY2021 Q3 FY2021 Q4 FY2021 • Recovery in fu

  8. Slide 8: Outlook FY2022

    Outlook FY2022 Comparable revenue growth1, 2 Adj. basic earnings per share2 19.3% Growth ex antigen: 17 to 23% €2.08 to €2.20 €2.03 Ex antigen: 5 to 7% Antigen ~7.5% 0 to 2% Antigen accretion accretion ~€0.30 2021 2022E 2021 2022E • Imaging growth at 5 to 8% • Imaging margin at 22 to 23% • Diagnosti

  9. Slide 9: Appendix

    Appendix Q4 FY2021 Unrestricted © Siemens Healthineers AG, 2021 l 9

  10. Slide 10: Q4 – a strong finish in a record year

    Q4 – a strong finish in a record year Revenue (€m) Adjusted basic earnings per share (€) +14.4% Y-o-Y +13% Comparable (Adj. EPS growth ex-FX) Growth1 5,164 Y-o-Y +10% 3,876 0.53 0.48 Q4 FY2020 Q4 FY2021 Q4 FY2020 Q4 FY2021 • 14% revenue growth in Q4 with excellent growth in Diagnostics, and • Adj. b

  11. Slide 11: Cash conversion rate in FY21 at ~1 – Q4 at 0.75 after three very good previous quarters

    Cash conversion rate in FY21 at ~1 – Q4 at 0.75 after three very good previous quarters Q4 FY21 Siemens Healthineers EBIT to Free Cash Flow (€m) Imaging 0.8 CCR1 Diagnostics <0 Varian 3.2 Adv. Therapies 0.9 CCR1 0.75 906′ -105′ 835′ 763′ 143′ -272′ 31′ 623′ 42′ 569′ 141′ 275′ -223′ -42′ 380′ -231′ H

  12. Slide 12: FY21 balance sheet and net debt bridge

    FY21 balance sheet and net debt bridge Net debt overview Capital structure development in FY21 (in €bn) in €bn Sep 30, 2020 Sep 30, 2021 Leverage1 0.9x 3.5x Cash and cash equivalents 0.7 1.3 12.8 Current receivables from the -0.8 0.9 Siemens Group from financing 3.3 0.6 activities Short-term and lon

  13. Slide 13: SHS loan maturity profile

    SHS loan maturity profile SHS loans with Siemens Group as of Sep 30th 20211 (in €m) Comments Other ▪ Total loan volume ~€13bn equivalent EUR ▪ Average interest rate ~0.5%3 USD 2,174 88 Top 10 loans Volume Volume Interest 1,730 Currency Maturity in m in €m rate 20 1,560 1,5142 EUR €700 €700 0.10%4 FY

  14. Slide 14: Provisions for pensions unchanged, including Varian pension commitments

    Provisions for pensions unchanged, including Varian pension commitments Q4 FY2021 Key financials – Pensions and similar obligations Q1 Q2 Q3 Q4 in €bn1 FY2018 FY2019 FY2020 FY2021 FY2021 FY2021 FY2021 Defined benefit obligation (DBO) (3.4) (3.8) (3.8) (3.9) (3.8) (4.1) (4.1) Fair value of plan asset

Siemens Healthineers — Q4 FY2021 Earnings Presentation on 6ix